We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Screening Tests Detect Cystic Fibrosis Gene Mutations

By LabMedica International staff writers
Posted on 22 Jul 2009
Print article
Two cystic fibrosis (CF) kits can quickly and accurately detect up to 39 of the most common cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations from a child or parent's blood sample, or bloodspot. They provide assistance in CF screening of newborns, confirmatory diagnostic testing in newborns and children, and can be used for carrier testing in adults of reproductive age.

The kits are known as the xTAG Cystic Fibrosis 39 Kit v2 and xTAG Cystic Fibrosis 71 Kit v2. The latter screens for all of the genetic mutations in the xTAG Cystic Fibrosis 39 Kit v2 plus an additional 32 mutations typically found in specific populations. To date, more than 1,500 disease-causing CFTR mutations have been identified.

The xTAG tests are designed to be fast and easy for use, requiring only about one hour of hands-on time to process 48 purified samples. They enable physicians to select the CFTR gene mutations for which they want to test. Additionally, reflex tests are incorporated in these kits. All results are available for analysis at each run. With validated performance criteria, the xTAG Cystic Fibrosis 39 Kit v2 and xTAG Cystic Fibrosis 71 Kit v2 are accurate and reproducible.

Luminex Corp. (Austin, TX, USA), a company dealing in multiplexed solutions, announced that it has launched the two new CF tests in Europe as CE marked in vitro diagnostic (IVD) products. Milan Macek, professor of medical and molecular genetics, division of clinical molecular genetics and the national cystic fibrosis center at University Hospital Motol and Second School of Medicine Charles University (Prague, Czech Republic), explained, "The geographic distribution of CFTR gene mutations differs significantly among the European populations. Some are ubiquitous, some are rare, and some are population-specific. The possibility of having a test that can cover a wide range of mutations found in different ethnic groups is very important and will allow doctors to have better confidence [in] CF diagnosis, especially when we have cases where the ethnicity of the patient is difficult to assess."

Cystic fibrosis causes the body to produce thick mucus that can clog the lungs and affect the digestive system. The chronic disease is inherited when both of a child's parents carry the CFTR gene mutation that causes CF. Approximately 36,000 Europeans have cystic fibrosis and each year 2,500 children with the disease are born. Although CF is most common among western European populations, it can affect people of any race. According to European Cystic Fibrosis Society, as many as one in 30 Europeans are carriers of a CF-causing gene mutation.

Information about the new xTAG tests was presented at the 2009 European Cystic Fibrosis Conference, which was held June 10-13, 2009 in Brest, France.

Related Links:
Luminex Corp.
University Hospital Motol and Second School of Medicine Charles University


New
Gold Member
Thyroid Stimulating Hormone Assay
TSH EIA 96 Test
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
New
Hematocrit Centrifuge
4088M1 - Zip Compact

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The Accelerate Arc System has been granted US FDA 510(k) clearance (Photo courtesy of Accelerate Diagnostics)

Automated Positive Blood Culture Sample Preparation Platform Designed to Fight Against Sepsis and AMR

Delayed administration of antibiotics to patients with bloodstream infections significantly increases the risk of morbidity and mortality. For optimal therapeutic outcomes, it is crucial to rapidly identify... Read more

Pathology

view channel
Image: Confocal- & laminar flow-based detection scheme of intact virus particles, one at a time (Photo courtesy of Paz Drori)

Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. Antigen-based tests provide... Read more

Industry

view channel
Image: The GeneXpert system’s fast PCR Xpert tests can fight AMR and superbugs with fast and accurate PCR in one hour (Photo courtesy of Cepheid)

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) is responsible for over one million deaths globally each year and poses a growing challenge in treating major infectious diseases like tuberculosis, Escherichia coli (E.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.